Overview. Presentation and prognosis Outcomes with standard therapy
|
|
- Shawn Ray
- 5 years ago
- Views:
Transcription
1 Emerging Therapies for Triple Negative Breast Cancer Joseph A. Sparano, MD Director, Breast Evaluation Center Montefiore-Einstein Cancer Center Professor of Medicine & Women s Health Albert Einstein i College of Medicine i Bronx, New York
2 Overview Presentation and prognosis Outcomes with standard therapy Biological agents Bevacizumab, cetuximab DNA damage Inducers of DNA damage (alkylators, platinums) Inhibitors of DNA repair (gemcitabine) PARP inhibitors Other agents 2
3 Triple-Negative Disease Compared with Other Phenotypes in the California i Cancer Registry Study Bauer et al. Cancer 2007: 109; 721 Population-based study 6370 with triple-negative disease compared with 44,704 other cases (12% of all cases) Findings more likely to be associated with Younger age (<40): OR 1.53 Non-Hispanic black (OR 1.77) or Hispanic (OR 1.23) Higher grade (72% grade 3) Poorer 5 year RFI irrespective of stage TNBC: 76% (similar to 76% for HER2-Pos) HR-Pos, HER2-Neg: 94%
4 Nomenclature: Basal-like and Triple-Negative Not all triplenegative are basal-like ~ 10-20% of triple-negative have a non- basal genomic profile IHC 15-40% of basal are not triple-negative Basal-like and triple-negative ~ ER+, PR+, or Array HER2+ on clinical assays -Terms are not synonymous -Terms are often used interchangeably % discordance across several studies Seal MD et al. Cancer J 2010; 16: 12-16
5 TNBC comprised of diverse molecular subtypes 0.3 Preliminary* Relativ ve frequency in panel basal claudinlow ERBB2 luminala luminalb normallike * Validation ongoing Affymetrix gene expression profiling of FFPE samples Intrinsic subtypes assigned using Sorlie et al, PNAS, 2003 data set and claudin-low classifier (Prat et al., BCR, 2010) [courtesy of J. Theilhaber and D. Bergstrom, Sanofi]
6 BLBC/TNBC Shares Clinical and Pathologic Features with BRCA-1-Related Breast Cancers Characteristics ti Hereditary BRCA1 Basal-like/Triple- negative 1,2,3 ER/PR/HER2 status Negative Negative TP53 status Mutant Mutant BRCA1 status Gene-expression pattern Tumor histology Chemosensitivity to DNA-damaging agents Mutational inactivation* Basal-like Poorly differentiated (high grade) Highly sensitive Diminished expression* Basal-like Poorly differentiated (high grade) Highly sensitive *BRCA1 dysfunction due to germline mutations, promoter methylation, or overexpression of HMG or ID4 4 1 Perou et al. Nature. 2000; 406: Cleator et al.lancet Oncol 2007;8: Sorlie et al. Proc Natl Acad Sci U S A 2001;98: Miyoshi et al. Int J Clin Oncol 2008;13:
7 Timing of Recurrence in Triple Negative Disease vs. Other Phenotypes Dent et al. Clin Can Res 2007; 13: 4429
8 DFS and OS After Adjuvant AC-Taxane Therapy: Results by Breast Cancer Subtype in All Treatment Arms in Trial E1199 Sparano et al. NEJM year DFS 5 year OS HR-Pos, HER2-Neg 83% 91% Triple Negative 69% 77% HER2-Positive * 78% 86% * No adjuvant trastuzumab 8
9 J Clin Oncol 2009; 27:
10 Treatment No. TNBC Non- TNBC Single agent taxane % 2% FAC/FAC/AC % 5% T-FAC/T-FEC % 17% 10
11 DNA Damage/Repair 11
12 BRCA1-Deficient Cells are Hypersensitive to Cisplatin BRCA1 deficient cells have defect in DNA DS repair BRCA1 deficient cells were more sensitive to cisplatin compared to other cell lines BRCA1 loss increases sensitivity to DNA damaging agents like cisplatin HCC1937, BRCA-deficient cell line MCF-7, 7hormone-sensitive MDA-MB230, hormone-insensitive Tassone P et al. Br J Cancer 2003; 88:
13 pcr Rates after Single Agent Cytotoxic Neoadjuvant Therapy in Triple Negative Disease Reference Agent No. PCR Garber et al. Cisplatin 75 mg/m (22%) JCO 2009 q 3 wks x 4 Martin ASCO 2010 Doxorubicin 75 mg/m2 q 3wks x 4 Docetaxel 100 mg/m2 q 3 wks x (10%) 28 8 (27%) 13
14 pcr in BRCA1-Associated Breast Cancer Receiving i Neoadjuvant Chemotherapy J Clin Oncol. 2010; 28: Epub 2009 Dec 14. Registry of 6,903 patients 102 BRCA1 founder mutation and received neoadjuvant chemotherapy 24 (24%) has a pcr CMF: 1 of 14 (7%) AT (docetaxel): 2 of 25 (8%) AC of FAC: 11 of 51 (22%) Cisplatin: 10 of 12 (83%) 14
15 N Eng J Med 2009; 3060:
16 J Clin Oncol 1997; 15:
17 J Clin Oncol 1997; 15:
18 J Clin Oncol 1999; 17:
19 J Clin Oncol 1999; 17:
20 ASCO 2009, abstract
21 21
22 22
23 tango Treatment Schema E C T vs. E C G T Epirubicin i 90mg/m 2 Paclitaxel l 175mg/m 2 d1 Cyclophosphamide 600mg/m 2 Gemcitabine 1250mg/m 2 d1&8 Q 21/7 Q 21/7, P-then-G seq admin d1
24 Disease-Free Survival (DFS) No significant difference between treatments HR=1.0 (95% CI )
25 J Clin Oncol 2010; 328:
26 Other Adjuvant Strategies in TNBC BEATRICE (N=2581) Adjuvant chemotherapy +/- bevacizumab TITAN (N=1800) AC plus weekly paclitaxel x 12 vs. ixabepilone x 4 PACS08 (N=2500) FEC100 x 3 + docetaxel x 3 vs. ixabepilone x 3 26
27 Biological Agents +/- Taxanes or DNA Damaging Agents 27
28 E2100: Weekly paclitaxel alone or plus bevacizumab as first-line therapy for metastatic breast cancer outcomes by ER/PR expression PFS by Treatment ER Negative, PgR Negative ER/PR Negative PFS Probability PB P P+B P All 17% 34% P < Medians: 4.7, 8.6 Measurable 17% 41% (79%) PFS Probability ER and/or PR Positive Months P P+B PFS by Treatment ER Positive, PgR Positive PB P P < Medians: 7, 14.1 All 23% 37% Measurable (46%) 30% 51% Months 28
29 BALI-1 Trial Schema Eligibility (N = 173) Metatstatic triple- negative breast cancer (mtnbc) R 2:1 1 prior chemotherapy for metastatic disease allowed Cetuximab/cisplatin (n = 115) Cetuximab 400 mg/m 2 initial 250 mg/m 2 weekly Cisplatin 75 mg/m 2 d1 q3wk up to 6 cycles Cisplatin (n = 58)* Cisplatin 75 mg/m 2 d1 q3wk up to 6 cycles * Crossover allowed: 31 patients receiving cisplatin alone switched to cetuximab/ cisplatin after first disease progression. Baselga J et al. Proc SABCS 2010;Abstract PD01-01.
30 Response Rates Best Response Cetuximab + Cisplatin (n = 115) Cisplatin Alone (n = 58) Overall response (ORR)* 20.0% 10.3% Complete response (CR) Partial response (PR) 1.7% 18.3% 1.7% 8.6% Stable disease 41.7% 31.0% Progressive disease 29.6% 53.4% Odds ratio (95% CI) 2.13 ( ) 59) p-value 0.11 *ORR > 20% was a prespecified criterion to demonstrate superiority of cetuximab + cisplatin over cisplatin alone. Baselga J et al. Proc SABCS 2010;Abstract PD01-01.
31 Progression-Free Survival (PFS) ree survival Prob ability of pr rogression-f Cetuximab + cisplatin Cisplatin Cetuximab + cisplatin Cisplatin n = 115 n = 58 Number of Events Median PFS, months [95% CI] [ ] 43] [ ] 28] HR [95% CI] p-value 0.67 [ ] Months With permission from Baselga J et al. Proc SABCS 2010;Abstract PD01-01.
32 Overall Survival (OS) urvival of overall s Probability 1.0 Cetuximab cisplatin Cisplatin n = 115 n = Number of Events Median OS, months [95% CI] [ ] 6] [ ] HR [95% CI] p-value 0.82 [ ] Cetuximab + cisplatin Cisplatin Months With permission from Baselga J et al. Proc SABCS 2010;Abstract PD01-01.
33 PARP Inhibitors 33
34 History of Poly(ADP-ribose) Polymerase (PARP) as a Therapeutic Target Discovery of PARP 1963: Nuclear enzymatic activity that synthesizes an adenine containing RNA- like polymer (Chambon et al) : Confirmed by others, polymer identified as PARP (Nishizuka et al) Discovery of PARP Function 1979: PARP activated t by DNA strand breaks (Juarez-Salinas et al) 1980: PARP participates in DNA repair (Durkacz et al) 1986: PARP1 hyperactivation lead to NAD+ and ATP depletion after DNA damage, promoting metabolic cell death (parthanosis) (David et al) 2000: PARP knockouts confirm role in DNA repair (Shail et al) Discovery of PARP Inhibitors 1980: PARP inhibitors enhance alkylators (Durkacz et al) 2005: PARP inhibitors toxic to BRCA deficient cells (Bryant et al, Farmer et al) 2009: Clinical trials demonstrating PARPi activity in BRCA-deficient breast cancer and in combination with DNA damaging agents in sporadic TNBC (Tutt et al, O Shaugnessy et al) 34
35 Poly (ADP-ribose) Polymerase (PARP) DNA binding domain Automodification domain Catalytic Domain PARP homology domain PARP-1 Nuclear protein 3 functional domains Amino terminal: DNA binding Automodification: autoribosylation (protein-protein interactions) C-terminal: catalytic domain transfer ADP-ribose from NAD+ to protein acceptors, forming padpr (2x higher charge density than DNA) DNA damage PARPs recruited to altered DNA, catalytic activity up to 500-fold padpr localization to DNA and recruitment of proteins (eg, XRCC1) which assemble and activate DNA base excision repair NAD+ and ATP depletion contribute to cell death
36 DNA Damage Repair Pathways Single Singlestrand strand breaks breaks Double Doublestrand strand breaks breaks Type of damage: Bulky adducts O6- alkylguanine breaks breaks (SSBs) (SSBs) (DSBs) (DSBs) Insertions & deletions Base Base excision excision repair repair Recombination Recombination repair repair Repair pathway: Nucleotide- Mismatch repair Direct PARP PARP HR HR NHEJ NHEJ excision repair reversal PARP PARP ATM ATM BRCA BRCA DNA DNA-PK PK Repair enzymes: XP, polymerases MSH2, MLH1 AGT
37 37
38 PARP-1 Inhibition Increases DNA DS Damage DNA SSB pol β PNK 1 PARP XRCC1 Replication (S-phase) LigIII Inhibition of PARP-1 prevents recruitment of repair factors to repair SSB DNA DSB
39 PARP Inhibitors: Mechanisms of Action Synthetic ti lethality lit BRCA1/2 loss or other HR proteins (eg, RAD51) PTEN loss Inhibit repair of DNA damage DNA damaging agents (eg, alkylators/platinum) Topoisomerase I inhibitors Transcriptional regulation 39
40 Synthetic Lethality: Selective effect of PARP-1 inhibition on cancer cells with BRCA1 or BRCA2 mutation DNA Damage Base Excision Repair PARP Inhibitor Homologous Recombination BRCA Mutation Cell survival Cancer cell death
41 BRCA-Deficient Cells are Hypersensitive to PARP Inhibition 41 Bryant HE et al. Nature 2005;434:913-7
42 42
43 PARP Inhibitors H 2 N O R1 O NH N Olaparib R2 Benzamide Inhibitors 3-AB, PD N N Abbott ABT-888 (Veliparib) O H N NH 2 O H N O F N N H H H Pfizer AG BSI-201 (Iniparib) N Cephalon CEP-6800
44 Biomarkers of PARP Inhibitor Effects Poly ADP ribose PAR Indirect measure of PARP inhibition ELISA - PBMC Gamma H2AX Reflective of DNA DS breaks FLT-PET (3 -[F-18]Fluoro-3 deoxythmidine) Cellular l uptake of FLT regulated by cytosolic thymidine kinase I Key enzyme in pyrimidine salvage pathway of DNA replicaiton FLT update dependent on cell proliferation 44
45 45
46 Phase II Study of BSI Plus Chemotherapy in TNBC: Efficacy Data Efficacy Response BSI gem/carbo (n=42) Gem/carbo (n=44) p value ORR 20(48%) 6 (22%) 0.02 CBR 26 (62%) 9 (21%) Survival n=57 n=59 mpfs mos 6.9 months 3.3 months < months 5.7 months CBR: clinical benefit rate (CR+PR+SD) O Shaughnessy et al., NEJM,
47 Iniparib* (BSI-201) A novel, investigational, anti-cancer agent In triple negative breast cancer cell lines 1-4 : Induces cell cycle arrest in the G2/M phase Induces double strand DNA damage H2AX foci but does not inhibit PARP 1 and 2 at physiologic drug concentrations Potentiates cell-cycle arrest induced by DNA damaging agents, including platinum and gemcitabine Physiologic targets of iniparib and its metabolites are under investigation Clinical Data: In a randomized phase 2 study, addition of iniparib to gemcitabine/carboplatin improved CBR, ORR, PFS and OS in patients with mtnbc 5 No potentiation of chemotherapy-related toxicities when iniparib is combined with gemcitabine/carboplatin *Iniparib is the United States Adopted Name (USAN) for the investigational agent BSI Ossovskaya V, et al. SABCS 2010, San Antonio, TX. Poster P ; 2. Ossovskaya V, et al. AACR 2009, Denver, CO. Abstract 5552; 3. Ossovskaya V, et al. AACR 2011, Orlando, FL. Abstract LB-401; 4. Ji et al. AACR 2011, Orlando, FL. Abstract 4527; 5. O Shaughnessy J, et al. N Engl J Med 2011; 364:
48 Schema Study Design: Multi-center, randomized open-label Phase III Trial N = 519 Study Population: Stage IV TNBC ECOG PS 0 1 Stable CNS metastases allowed 0-2 prior chemotherapies for mtnbc R Gem/Carbo (GC) (N= 258) Gemcitabine 1000 mg/m 2 IV d 1, 8 Carboplatin AUC2 IV d 1, 8 21-day cycles Crossover allowed to GCI following Disease Progression* (central review) Randomization stratified by prior chemo in the metastatic setting: 1 st -line (no prior therapy) 2 nd /3 rd -line (1-2 prior therapies) Gem/Carbo + Iniparib (GCI) (N= 261) Gemcitabine mg/m2 IV d 1, 8 Carboplatin - AUC2 IV d 1, 8 Iniparib mg/kg IV d 1,4,8,11 21-day cycles *Prospective central radiology review of progression required prior to crossover 96% (n=152) of progressing patients crossed over to GCI at time of primary analysis NCT
49 Efficacy Endpoints ITT population PFS Median PFS, mos (95% CI) GC (N=258) 4.1 (3.1, 4.6) GCI (N=261) 5.1 (4.2, 5.8) HR (95% CI) 0.79 (0.65, 0.98) p-value Pre-specified alpha = OS GC (N=258) GCI (N=261) Median OS, mos (95% CI) HR (95% CI) (9.2, 12.1) (10.6, 12.9) 088( (0.69, 112) 1.12) p-value 0.28 Pre-specified alpha = 0.04 urvival Probability of Pro ogression Free S ity of Survival Probabili Months Since Study Entry No. at risk GC GCI Months No. at risk GC GCI
50 Overall Response Rate* ITT Population GC GCI Response, n (%) N = 258 N = 261 Complete response 4 (1.6) 5 (1.9) Partial response 74(29) 83 (32) Stable disease 89 (35) 99 (38) Progressive disease 62 (24) 62 (24) Inevaluable 29 (11) 12 (4.6) SD > 6 months 14 (5.4) 19 (7.3) ORR, n (%) 78 (30) 88 (34) (95% CI) (25 36%) (28 40%) Clinical Benefit Rate, n (%) [CR +PR +SD(> 6 mos)] 92 (36) 107 (41) * Independent central review, RECIST confirmation of response 50
51 Exploratory Analysis 1 st -line ITT Population 1 st -line = 57% of patients (297/519) PFS OS Pr robability of Pro ogression Free Su urvival GCI 5.6 mos (4.2, 6.9) GC 4.6 mos (3.9, 5.7) HR=0.88 (0.66, 1.13); 197 events al Probabi ility of Surviv GCI 12.4 mos (10.6, NE) GC 12.6 mos (11.9, NE) HR=1.1 (0.78, 1.56); 129 events No. at risk Months GC GCI Months
52 Exploratory Analysis 2 nd /3 rd -line ITT Population 2 nd / 3 rd -line = 43% patients (222/519) PFS OS Pro obability of Prog gression Free Sur rvival GCI 4.2 mos (3.8, 5.7) GC 2.9 mos (1.9, 4.1 ) HR=0.67 (0.5, 0.92); 169 events ity of Survival Probabili GCI 10.8 mos (9.7,13.1) GC 8.1 mos (6.6, 10) HR=0.65 (0.46, 0.91); 132 events No. at risk Months GC GCI Months
53 Multivariate Analysis - OS Evaluate impact of imbalances in specific baseline characteristics on OS per multivariate analyses as specified in the statistical analysis plan (SAP) Analyses based on : 1. Pre-specified baseline factors: age, disease burden, ECOG PS, line of therapy, race, time since diagnosis of mtnbc, visceral disease, and elevated alkaline phosphatase 2. Pre-specified baseline factors above - but replace time since diagnosis of mtnbc with Disease Free Interval from primary BC surgery to onset of metastatic disease Treatment Estimates for OS determined using Multivariate Cox Model ITT Population 1 st -line 2 nd /3 rd -line HR p HR p HR p Unadjusted Using pre-specified baseline factors Using pre-specified baseline factors with DFI replacement * * * * * * * p-value is Wald Chi-Square test
54 Other Strategies 54
55 VM Richon et al. Can Lett 2009
56 Palmieri et al. Clin Cancer Res 2009;15(19): ) 56
57 Effect of HDAC Inhibitor Vorinostat in Human Breast Cancer in Vivo Ramaswamy et al. Submitted 57
58 P7703: Vorinostat Induces Hyperacetylation In Vivo 58
59 Relationship Between GRB7 Expression and Recurrence in TNBC Sparano et al. Clin Cancer Res patients t with TNBC (central IHC) and 0-3 pos axillary nodes in E2197 Treated with adjuvant doxorubicin/cyclophosphamide or dox/docetaxel GRB7 5 year Recurrence Rate 95% C.I. rd Ratio 2 1 Low 10.5% 7.8%, 14.1% Log Haza -1 0 High 20.4% 16.5%, 25.0% GRB7-2 59
60 Results: Estimated Hazard Ratios and 95% C.I. from Joint Models for Recurrence Rates in TNBC Model I Model II Age 45 vs. > (0.17,1.42) 0.49 (0.17,1.46) Age vs. > (0.25,1.84) 0.63 (0.22,1.78) Nodes 1 vs (1.17,3.57) 2.27 (1.32,3.92) Nodes 2-3 vs (0.65,3.83) 1.96(0.86,4.47) 47) Grade Poor vs. Mod/Well 1.62 (0.53,4.95) 1.43 (0.51,3.98) Tumor size >2 vs. 2 cm 1.97 (1.10,3.55) 1.95 (1.09,3.47) GRB7 x+2 vs. x 3.41 (1.78,6.53) p= GRB7 High vs. Low 2.31 (130411) (1.30,4.11) p=
61 Grb7 Adapter Protein Member of a family of adapter proteins no enzymatic activity calmodulin-binding protein with an SH2 (Src homology 2) domain that binds to phosphorylated RTKs and other protein targets role in signaling (EGFR, HER2), motility (ephrins), migration (focal adhesion kinase), and cell-matrix/cell-cell interactions (integrins) Share region with sequence homology to the Mig-10 C. elegans gene required for migration of neuronal cells in embryonic development suggests role for Grb7 in cell migration Grb7 present in focal adhesions bound and phosphorylated by focal adhesion kinase (FAK) critical for cell migration Grb7 also found in the cytoplasm interacts with other upstream binding partners, including ErbB2 role in regulation of cell proliferation Oncogene 2001; 20: 6315 BMC Structural Biol 2007; 7: 58 61
62 GRB7 Peptide Inhibitor Inhibits cell migration and proliferation of cell lines with varying Her2 expression (SK-BR-3, MDA-MB-361, MDA-MB-231, ZR75-30) Enhances effects of doxorubicin and trastuzumab in the HER2- pos cell line (SK-BR-3) Effective in pancreatic xenograft model Porter et al. BMC Structural Biology 2007; 7: 58; Tanaka et al. JNCI 2006; 98: 491; Pero et al. Br J Cancer 2007; 96:
63 Effect of GRB7 Inhibitor (G7-18NATE) on Basal Cell Lines Kenny et al. BCRT 2011 MDA- MB-468 MDA- MB-468 Invasion Transwell Matrigel Assay Motility Monoloyer Wound Healing Assay Kenny et al. AACR
64 Effect of GRB7 Inhibitor (G7-18NATE) on Basal Cell Lines Proliferation 3D Culture MDA- MB-468 Kenny et al. CCR 2011
65 Significantly Higher RNA Expression in TNBC vs. HR+, HER2- Disease (Top 10%) Sparano et al. Clin Can Res 2011 Cell cycle/proliferation/mitosis Markers: (eg, BUB1, MKI67) Targets (eg, AURKB, PLK1, KIFC1) DNA repair (CHEK1, RAD45L, TOP2A) Transcriptional regulation (FOXM1, MYBL2, PTTG1) Invasion (CTSL2, MMP12) Motility y( (KIFC2) Hypoxia (CA9) Signaling (DEPDC1) Ubiquitin-mediated protein catabolism (CDC20) Cox proportional hazards model score tests; methods of Korn used to control false discovery rates (J Stat Planning Inference, 124: , 2004) 65
66 E2197 Results: Differentially Expressed Genes That are Potential Therapeutic Targets Gene Function Drugs AURKB Binds microtubule K fibers AZD1152, VX , near kinetichores AT9283 PLK1 Regulates G2/M transition BI6727, ON01910 KIFC1 Microtubule motor activity ARRY-250, ispinesib, SB CHK1 Regulates G2/M checkpoint AZD7762, PF FOXM1 G1 S and G2 M cell cycle Siomycin A phase progression; mitotic spindle integrity it 66
67 Conclusions: Management of TNBC and Emerging Therapies Anthracyclines, alkylators, taxanes play important role Aklylators l dose escalation not effective Gemcitabine no role as adjuvant therapy Capecitabine no role for adjuvant monotherapy Biological agents bevacizumab, EGFR inhibitors PARP inhibitors role remains to be defined Predictive markers? What level and/or duration of PARP inhibition is sufficient? PARPi plus other non-cytotoxic and/or cytotoxic agents? Other potential therapeutic targets HDAC inhibitors Others 67
Pathways Underlying Aggressive Breast Cancers
Origin of Breast Cancer Subtypes Pathways Underlying Aggressive Breast Cancers HER2 and ER can be expressed in any subtype. Triple Negative -- a mixture of subtypes Joyce O Shaughnessy, MD Baylor Sammons
More informationClinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC)
Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC) Eric P Winer, MD Disclosures for Eric P Winer, MD No real or apparent conflicts of interest to disclose Key Topics: PARP and
More informationTriple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
More informationTriple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008
Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer 15% 25% Triple Negative 20% HER2+ ER+ Low Grade
More informationBreast Cancer and Treatment Options in Patients with BRCA1/2 mutations. Olivia Pagani On behalf of Bella Kaufman
Breast Cancer and Treatment Options in Patients with BRCA1/2 mutations Olivia Pagani On behalf of Bella Kaufman Carrier Frequency Prevalence of an altered disease gene in a given population Background
More informationBreast : ASCO Abstracts for Review
Breast : ASCO 2011 Susana Campos, MD, MPH Dana Farber Cancer Institute Abstracts for Review Prevention Neoadjuvant Metastatic Brain mets LBA 504: Exemestane for primary prevention of breast cancer in postmenopausal
More informationCarrier Frequency. Breast Cancer and Treatment Options in Patients with BRCA1/2 mutations. Olivia Pagani On behalf of Bella Kaufman
Breast Cancer and Treatment Options in Patients with BRCA1/2 mutations Olivia Pagani On behalf of Bella Kaufman Carrier Frequency Prevalence of an altered disease gene in a given population 1 Background
More informationUpdate on Breast Cancer
Update on Breast Cancer William J. Gradishar, MD Professor of Medicine Robert H. Lurie Comprehensive Cancer Center Feinberg School of Medicine Northwestern University Overview PARP Inhibitors Neoadjuvant
More informationPARP inhibitors for breast cancer
PARP inhibitors for breast cancer Mark Robson, MD Memorial Sloan Kettering Cancer Center Agenda Mechanism of action Clinical studies Resistance mechanisms Future directions Poly (ADP-ribose) Polymerases
More informationENFERMEDAD AVANZADA Qué hacemos con el triple negativo? Nuevas aproximaciones
ENFERMEDAD AVANZADA Qué hacemos con el triple negativo? Nuevas aproximaciones Javier Cortes, Hospital Universitario Ramon y Cajal, Madrid Vall d Hebron Institute of Oncology (VHIO), Barcelona Triple Negative
More informationOverview and future horizons of PARP inhibitors in BRCAassociated. Judith Balmaña
Overview and future horizons of PARP inhibitors in BRCAassociated breast cancer Judith Balmaña PARP inhibitors: Mechanism of action Clinical development: Monotherapy In combination with chemotherapy Ongoing
More informationTherapeutic Targets for Triple- Negative Breast Cancer: Focus on Platinums and EGFR Inhibition
Therapeutic Targets for Triple- Negative Breast Cancer: Focus on Platinums and EGFR Inhibition Lisa A Carey, MD Disclosures for Lisa A Carey, MD No real or apparent conflicts of interest to disclose Basal-Like
More informationAlternativas terapéuticas en fenotipo triple negativo Javier Cortes, Hospital Universitario Ramon y Cajal, Madrid
Alternativas terapéuticas en fenotipo triple negativo Javier Cortes, Hospital Universitario Ramon y Cajal, Madrid Vall d Hebron Institute of Oncology (VHIO), Barcelona Triple Negative Breast Cancer Immunohistochemistry
More information非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和
資料 2 2 非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和 1 Preclinical studies Therapeutic Window: Efficacy/Toxicity Disease Specificity Subtype Specificity Combination: Concurrent/Sequential Therapeutic situation: Response/
More informationEmerging Therapies for Triple Negative Breast Cancer
Emerging Therapies for Triple Negative Breast Cancer Joseph A. Sparano, MD Professor of Medicine & Women s Health Albert Einstein College of Medicine Associate Chairman, Department of Oncology Montefiore
More informationSubtype-directed therapy of TNBC Global Breast Cancer Conference 2015 & 4th International Breast Cancer Symposium Jeju Island, Korea, April 2015
Subtype-directed therapy of TNBC Global Breast Cancer Conference 2015 & 4th International Breast Cancer Symposium Jeju Island, Korea, April 2015 Ruth M. O Regan, MD Visiting Professor and Division Chief
More informationTriple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationTargeting DNA repair in BRCA 1/2 and Triple Negative Breast Cancer
Targeting DNA repair in BRCA 1/2 and Triple Negative Breast Cancer Andrew Tutt, MB ChB, PhD Consultant Oncologist/Director Breakthrough Breast Cancer Research Unit King s Health Partners Academic Health
More information10/15/2012. Inflammatory Breast Cancer vs. LABC: Different Biology yet Subtypes Exist
Triple-Negative Breast Cancer: Optimizing Treatment for Locally Advanced Breast Cancer Beth Overmoyer MD Director, Inflammatory Breast Cancer Program Dana Farber Cancer Institute Overview Inflammatory
More informationEmerging Therapies for Triple Negative Breast Cancer
Emerging Therapies for Triple Negative Breast Cancer Joseph A. Sparano, MD Professor of Medicine & Women s Health Albert Einstein College of Medicine Associate Chairman, Department of Oncology Montefiore
More informationVirtual Journal Club. Ovarian Cancer. Reference Slides. Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies
Virtual Journal Club Ovarian Cancer Reference Slides Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies Mansoor R. Mirza, MD Copenhagen University Hospital Rigshospitalet
More informationDieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
What is hot in breast cancer brain metastases? Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands 8th Annual Brain Metastases Research and Emerging Therapy
More informationTriple negative breast cancer 2014 GASCO Annual meeting September 5 th 2014, Atlanta, GA
Triple negative breast cancer 2014 GASCO Annual meeting September 5 th 2014, Atlanta, GA Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology,
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationL Oncologo Sperimentatore nel Disegno e nella Conduzione dello Studio Clinico
L Oncologo Sperimentatore nel Disegno e nella Conduzione dello Studio Clinico Antonino Musolino U.O.C. Oncologia Medica Azienda Ospedaliero-Universitaria di Parma LA SETTIMANA DEL GOIRC Negrar, 29 Aprile
More informationNovel Chemotherapy Agents for Metastatic Breast Cancer. Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX
Novel Chemotherapy Agents for Metastatic Breast Cancer Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX New Chemotherapy Agents in Breast Cancer New classes of drugs Epothilones Halichondrin
More informationSystemic therapy of triple negative advanced breast cancer. Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Early Drug Development
Systemic therapy of triple negative advanced breast cancer Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Early Drug Development Outline State of the Art in the management of TN advanced
More informationManagement of Triple Negative Breast Cancer. Giuseppe Curigliano MD, PhD University of Milano and European Institute of Oncology
Management of Triple Negative Breast Cancer Giuseppe Curigliano MD, PhD University of Milano and European Institute of Oncology Outline Heterogeneity of TNBC Targeting TNBC by subtypes New antibody drug
More informationLocally Advanced Breast Cancer: Systemic and Local Therapy
Locally Advanced Breast Cancer: Systemic and Local Therapy Joseph A. Sparano, MD Professor of Medicine & Women s Health Albert Einstein College of Medicine Associate Chairman, Department of Oncology Montefiore
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More informationBrian T Burgess, DO, PhD, GYN Oncology Fellow Rachel W. Miller, MD, GYN Oncology
Brian T Burgess, DO, PhD, GYN Oncology Fellow Rachel W. Miller, MD, GYN Oncology Epithelial Ovarian Cancer - Standard Current Treatment: Surgery with De-bulking + Platinum-Taxane based Chemotherapy - No
More informationSYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER
SYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER Sunil Shrestha 1*, Ji Yuan Yang, Li Shuang and Deepika Dhakal Clinical School of Medicine, Yangtze University, Jingzhou, Hubei Province, PR. China Department
More informationNuevas estrategias de tratamiento en tumores con mutaciones de BRCA
Nuevas estrategias de tratamiento en tumores con mutaciones de BRCA Emilio Alba UGCI Oncología Hospital Universitario Regional y Virgen de la Victoria Facultad de Medicina. Málaga IBIMA ÍNDICE DE LA PRESENTACIÓN
More informationReview of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012
Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory
More informationPost-ASCO 2017 Cancer du sein Triple Négatif
Post-ASCO 217 Cancer du sein Triple Négatif A.Ladjeroud, K.Bouzid Centre Pierre et Marie Curie- Alger Oran, 3 Septembre 217 Phase III Investigation of Neoadjuvant Carboplatin ± Veliparib in Combination
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationExpert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer. Reference Slides
Expert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer Reference Slides Overview BRCA Mutations and Breast Cancer Patients with BRCA mutations have an estimated 55% to 65% cumulative
More informationTNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017
TNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017 The problem with TNBC 1. Generally more aggressive 2. ONLY chemotherapy 3. No other
More informationCustomizing Therapeutic Strategies in the Management of Metastatic Breast Cancer
Customizing Therapeutic Strategies in the Management of Metastatic Breast Cancer Vandana G Abramson, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Breast Cancer
More informationAVANCES EN EL TRATAMIENTO SISTEMICO DE LOS TUMORES BRCA-DEFICIENTES
AVANCES EN EL TRATAMIENTO SISTEMICO DE LOS TUMORES BRCA-DEFICIENTES Dra. Judith Balmaña Servicio de Oncología Médica Hospital Universitario Vall Hebron Barcelona jbalmana@vhio.net Preclinical evidence
More informationHER2-Targeted Rx. An Historical Perspective
HER2-Targeted Rx An Historical Perspective Trastuzumab: Front Line Rx for MBC Median 20.3 v. 25.1 mo P = 0.046 HR 0.8 65% of control patients crossed over Slamon D, et al. N Engl J Med, 2001; 344:783 Trastuzumab:Front-line
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationNovel Preoperative Therapies for HER2-Positive Breast Cancer. Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center
Novel Preoperative Therapies for HER2-Positive Breast Cancer Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center Key Findings to Date in the Neoadjuvant Therapy of HER2+
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationCáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre
Cáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre Recurrence of HER2-positive breast cancer (A) Time to
More informationCommon disease 175,000 new cases/year 44,000 deaths/year Less than 10% with newly diagnosed at presentation have stage IV disease Chronic disease,
Chemotherapy for Metastatic Breast Cancer: Recent Results HARMESH R. NAIK, MD. Karmanos Cancer Institute and St. Mary Hospital Metastatic breast cancer (MBC) Common disease 175,000 new cases/year 44,000
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationFinding the Positives in Triple-Negative Breast Cancer:
Finding the Positives in Triple-Negative Breast Cancer: A Three-Part Live CME Webcast Series Seminar I Wednesday, March 3, 2010 Faculty Clifford Hudis, MD Lisa A Carey, MD Seminar II Thursday, March 11,
More informationHealth Disparities Advances in Breast Cancer Treatment. Jo Anne Zujewski April 27, 2009
Health Disparities Advances in Breast Cancer Treatment Jo Anne Zujewski April 27, 2009 Disclaimer Breast Cancer Incidence 1994-2003 Breast Cancer Mortality 1994-2003 Access to Care Comorbidity Biology
More informationPROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND!
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico PROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND! INGRID A. MAYER, MD, MSCI Assistant
More informationCancer du sein métastatique et amélioration de la survie Pr. X. Pivot
Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot Date of preparation: November 2015. EU0250i TTP/PFS Comparaisons First line metastatic breast cancer Monotherapy Docetaxel Chan 1999
More informationHDAC Inhibitors and PARP inhibitors. Suresh Ramalingam, MD Associate Professor Chief of Thoracic Oncology Emory University School of Medicine
HDAC Inhibitors and PARP inhibitors Suresh Ramalingam, MD Associate Professor Chief of Thoracic Oncology Emory University School of Medicine Histone Acetylation HAT Ac Ac Ac Ac HDAC Ac Ac Ac Ac mrna DACs
More informationRole of chemotherapy in BRCA and Triple negative breast cancer. Fernando Moreno Servicio de Oncología Médica Hospital Clinico San Carlos
Role of chemotherapy in BRCA and Triple negative breast cancer Fernando Moreno Servicio de Oncología Médica Hospital Clinico San Carlos Association between TNBC & germline mutations in BRCA 1/2 TNBC is
More informationPARP inibitori nel trattamento del carcinoma mammario metastatico: recenti successi e prospettive future.
PARP inibitori nel trattamento del carcinoma mammario metastatico: recenti successi e prospettive future. Dr.ssa Angela Toss Centro Oncologico Modenese Università di Modena e Reggio Emilia MECHANISMS OF
More informationPostoperative Adjuvant Chemotherapies. Stefan Aebi Luzerner Kantonsspital
Postoperative Adjuvant Chemotherapies Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Does Chemotherapy Work in Older Patients? ER : Chemotherapy vs nil Age
More informationTriple-Negative Breast Cancer
June 2017 Triple-Negative Breast Cancer Amir Sonnenblick, MD, PhD Sharett institute of oncology Hadassah-Hebrew university medical center, Jerusalem, Israel This presentation is the intellectual property
More informationPrat et al, Mol Oncol 2011
Optimizing ther treatment of Triple Negative Breast Cancer: What Does the Future Hold? Ana M. Gonzalez-Angulo, M.D. Associate Professor Breast Medical Oncology Systems Biology Sao Paulo, Brazil, 3/2012
More information"BRCAness," PARP and the Triple-Negative Phenotype
"BRCAness," PARP and the Triple-Negative Phenotype Prof Alan Ashworth, FRS Disclosures for Professor Alan Ashworth, FRS Consulting Agreements GlaxoSmithKline, Pfizer Inc Patent AstraZeneca Pharmaceuticals
More informationTriple negative breast cancer -neoadjuvant and adjuvant systemic therapy
Triple negative breast cancer -neoadjuvant and adjuvant systemic therapy Sung-Bae Kim, MD, PhD Department of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul, Korea DISCLOSURE
More informationInhibidores de PARP Una realidad? dónde y cuando?
Inhibidores de PARP Una realidad? dónde y cuando? Alberto Ocana Hospital Universitario Albacete Centro Regional Investigaciones Biomédicas CIC-Salamanca DNA repair mechanisms DNA is continually exposed
More information4, :00 PM 9:00 PM
Consensus or Controversy? Clinical Investigators Provide Their Perspectives on Practical Issues and Research Questions in the Management of Breast Cancer Robert W Carlson, MD John Crown, MD Charles E Geyer
More informationAdvanced HER2+ Breast Cancer: New Options and How to Deploy Them. José Baselga MD, PhD
Advanced HER2 Breast Cancer: New Options and How to Deploy Them José Baselga MD, PhD HER2 signaling results in a multitude of cellular effects, including increased cellular proliferation HER2 HER3 RAS
More informationNeoadjuvantTreatment In BC When, How, Who?
NeoadjuvantTreatment In BC When, How, Who? Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service, MSKCC Professor of Medicine, Weill Cornell Medical College President, ASCO 15 Potential Benefits Of
More informationGene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA
Gene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA When Are Biomarkers Ready To Use? Same Rules for Gene Expression Panels Key elements
More informationSystemic Therapy for Locally Advanced Breast Cancer
Systemic Therapy for Locally Advanced Breast Cancer Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology National University Cancer Institute, Singapore Clinical Care Senior Principal
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More informationDR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
More information2/21/2016. Cancer Precision Medicine: A Primer. Ovarian Cancer Statistics and Standard of Care in 2015 OUTLINE. Background
Cancer Precision Medicine: A Primer Rebecca C. Arend, MD Division of Gyn Oncology OUTLINE Background Where we are Where we have been Where we are going Targeted Therapy in Ovarian Cancer How to Individualized
More informationThe Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now?
1 The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now? Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program
More informationBiomarkers for HER2-directed Therapies : Past Failures and Future Perspectives
Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast
More informationHER2-positive Breast Cancer
HER2-positive Breast Cancer Multiple choices what to use when? Thomas Ruhstaller Brustzentrum St. Gallen Adjuvant setting NCIC MA5 N Engl J Med 06, 2103 6 x CEF can 6 x CMF oral HER2 + pg schlecht in allen
More informationPIK3CA Mutations in HER2-Positive Breast Cancer
2016.4.29. GBCC PIK3CA Mutations in HER2-Positive Breast Cancer Seock-Ah Im, MD, PhD. Department of Internal Medicine Seoul National University Hospital Contents Introduction TCGA data HER2 signaling pathway
More informationQuestion 1 A. ER-, PR-, HER+ B. ER+, PR+, HER2- C. ER-, PR+, HER2- D. ER-, PR-, HER2- E. ER-, PR+, HER2+
Triple Negative Breast Cancer Laura C. Collins, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA Question 1 The tumor depicted on the next slide
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationPARP Inhibition. DNA Repair Machinery
UNIVERSITY UNIVERSTY OF TORINO OLOGICAL SCIENCES PARP Inhibition Silvia Novello, MD PhD University of Torino Italy Thoracic Oncology Unit silvia.novello@unito.it OLOGICAL SCIENCES DNA Repair Machinery
More informationPatient-Centric Science-Based Performance-Driven
Patient-Centric Science-Based Performance-Driven Cowen & Co. 38 th Annual Health Care Conference Michael Pehl, President and Chief Executive Officer March 12, 2018 Forward-Looking Statements This presentation,
More informationTriple Negative Breast Cancer
GASCO 2016 San Antonio Breast Cancer Symposium Review Triple Negative Breast Cancer Amelia Zelnak, MD, MSc Atlanta Cancer Care Northside Hospital Cancer Institute Disclosures: consultant for Novartis,
More informationSystemic Therapy Considerations in Inflammatory Breast Cancer
Systemic Therapy Considerations in Inflammatory Breast Cancer Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel Disclosures Roche: Speakers bureau,
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationTarge:ng HER2 in Metasta:c Breast Cancer in 2014
Targe:ng HER2 in Metasta:c Breast Cancer in 2014 Kimberly L. Blackwell MD Professor Department of Medicine and Radia:on Oncology Duke University Medical Center Director, Breast Cancer Program Duke Cancer
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationConsiderations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationTNBC: Current Challenge and Perspectives. Henry L Gomez MD, PhD
TNBC: Current Challenge and Perspectives Henry L Gomez MD, PhD What Is a Triple-Negative Breast Cancer (TNBC)? Triple negative : ER negative, PgR negative, HER2 negative Depending on thresholds used
More informationRecent Update in Management of Breast Cancer: Medical Oncology. Jin Hee Ahn, M.D., PhD. 23-April-2015
2015 GBCC & 4 th IBCS 1/37 Recent Update in Management of Breast Cancer: Medical Oncology Jin Hee Ahn, M.D., PhD. 23-April-2015 Department of Oncology, Asan Medical Center, UUCM, Seoul, Korea 2/37 3/37
More informationESMO Preceptorship Breast Cancer. Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Early Drug Development Istituto Europeo di Oncologia
ESMO Preceptorship Breast Cancer Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Early Drug Development Istituto Europeo di Oncologia Outline Rational for immune-based therapy in BC How to
More informationEmerging Advances in Metastatic Breast Cancer
Emerging Advances in Metastatic Breast Cancer Bryan P. Schneider, MD Assistant Professor of Medicine & Medical Molecular Genetics IU Simon Cancer Center AT LEAST THREE types of breast cancer TNBC HER2+
More information6/13/17. Disclosures. Treating Breast Cancer in People with Mutations. Off Label Use. I will be discussing off label use of medications today.
Treating Breast Cancer in People with Mutations Steven J. Isakoff, MD, PhD Massachusetts General Hospital Cancer Center June 9, 2017 sisakoff@partners.org Disclosures Company ² Myriad Genetics ² AbbVie
More informationAnthracyclines for Breast Cancer? Are Adjuvant Anthracyclines Dispensible? Needs to be Answered in a Large Prospective Trial
Anthracyclines for Breast Cancer? Are Adjuvant Anthracyclines Dispensible? Needs to be Answered in a Large Prospective Trial Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Dallas, TX Early Breast Cancer
More informationBreast Cancer Immunotherapy. Leisha A. Emens, MD PhD Johns Hopkins University Bloomberg Kimmel Institute for Cancer Immunotherapy
Breast Cancer Immunotherapy Leisha A. Emens, MD PhD Johns Hopkins University Bloomberg Kimmel Institute for Cancer Immunotherapy Conflict of Interest I have the following financial relationships to disclose:
More informationSystemic therapy: HER-2 update. Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven
Systemic therapy: HER-2 update Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven New drugs Strategic issues Specific anti-her2 drugs Lapa$nib /Nera$nib Baselga & Swain,
More informationBreast Cancer: ASCO Poster Review
Breast Cancer: ASCO Poster Review Carmen Criscitiello, MD, PhD Istituto Europeo di Oncologia Milano HER2+ SUBTYPE Research questions in early HER2+ BC De-escalation of toxicity without compromising efficacy
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationContemporary Classification of Breast Cancer
Contemporary Classification of Breast Cancer Laura C. Collins, M.D. Vice Chair of Anatomic Pathology Professor of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Outline
More informationCurrent and Future Perspectives in Treatment of Metastatic Triple Negative Breast Cancer (TNBC) Yeon Hee Park M.D., Ph.D.
Current and Future Perspectives in Treatment of Metastatic Triple Negative Breast Cancer (TNBC) Yeon Hee Park M.D., Ph.D. Breast Cancer Center, Medical Oncology Samsung Medical Center, Sungkyunkwan University
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationAssessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint
Assessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint William J. Gradishar, MD Professor of Medicine Robert H. Lurie Comprehensive Cancer Center of Northwestern University Classical
More informationInterviews are based on data presented at the 2012 American Society of Clinical Oncology Annual Meeting, June 1-5, 2012, Chicago, Illinois* *PeerVoice is an independent publisher of conference news and
More information